Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial

医学 肺癌 内科学 人口 肿瘤科 意向治疗分析 随机对照试验 临床终点 不利影响 环境卫生
作者
Ahmet Sezer,Saadettin Kılıçkap,Mahmut Gümüş,Igor Bondarenko,Mustafa Özgüroğlu,Miranda Gogishvili,Hacı Mehmet Türk,İrfan Çiçin,Dmitry Bentsion,Oleg Gladkov,Philip R. Clingan,Virote Sriuranpong,Naiyer A. Rizvi,Bo Gao,Siyu Li,Sue Lee,Kristina McGuire,Chieh-I Chen,Tamta Makharadze,Semra Paydaş
出处
期刊:The Lancet [Elsevier BV]
卷期号:397 (10274): 592-604 被引量:794
标识
DOI:10.1016/s0140-6736(21)00228-2
摘要

Background We aimed to examine cemiplimab, a programmed cell death 1 inhibitor, in the first-line treatment of advanced non-small-cell lung cancer with programmed cell death ligand 1 (PD-L1) of at least 50%. Methods In EMPOWER-Lung 1, a multicentre, open-label, global, phase 3 study, eligible patients recruited in 138 clinics from 24 countries (aged ≥18 years with histologically or cytologically confirmed advanced non-small-cell lung cancer, an Eastern Cooperative Oncology Group performance status of 0–1; never-smokers were ineligible) were randomly assigned (1:1) to cemiplimab 350 mg every 3 weeks or platinum-doublet chemotherapy. Crossover from chemotherapy to cemiplimab was allowed following disease progression. Primary endpoints were overall survival and progression-free survival per masked independent review committee. Primary endpoints were assessed in the intention-to-treat population and in a prespecified PD-L1 of at least 50% population (per US Food and Drug Administration request to the sponsor), which consisted of patients with PD-L1 of at least 50% per 22C3 assay done according to instructions for use. Adverse events were assessed in all patients who received at least one dose of the assigned treatment. This study is registered with ClinicalTrials.gov, NCT03088540 and is ongoing. Findings Between June 27, 2017 and Feb 27, 2020, 710 patients were randomly assigned (intention-to-treat population). In the PD-L1 of at least 50% population, which consisted of 563 patients, median overall survival was not reached (95% CI 17·9–not evaluable) with cemiplimab (n=283) versus 14·2 months (11·2–17·5) with chemotherapy (n=280; hazard ratio [HR] 0·57 [0·42–0·77]; p=0·0002). Median progression-free survival was 8·2 months (6·1–8·8) with cemiplimab versus 5·7 months (4·5–6·2) with chemotherapy (HR 0·54 [0·43–0·68]; p<0·0001). Significant improvements in overall survival and progression-free survival were also observed with cemiplimab in the intention-to-treat population despite a high crossover rate (74%). Grade 3–4 treatment-emergent adverse events occurred in 98 (28%) of 355 patients treated with cemiplimab and 135 (39%) of 342 patients treated with chemotherapy. Interpretation Cemiplimab monotherapy significantly improved overall survival and progression-free survival compared with chemotherapy in patients with advanced non-small-cell lung cancer with PD-L1 of at least 50%, providing a potential new treatment option for this patient population. Funding Regeneron Pharmaceuticals and Sanofi.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
峥嵘发布了新的文献求助10
刚刚
evergarden完成签到,获得积分10
刚刚
华仔的应助被吉林肽酶采纳,获得30
1秒前
3秒前
3秒前
3秒前
Zurini发布了新的文献求助10
3秒前
Hello的应助被小橘采纳,获得10
3秒前
CoCo完成签到 ,获得积分10
3秒前
Nole的应助被dit采纳,获得10
3秒前
沉静盼山完成签到,获得积分20
4秒前
上官若男的应助被周周采纳,获得30
4秒前
自觉的贞德关注了科研通微信公众号
5秒前
zz发布了新的文献求助10
6秒前
沉静盼山发布了新的文献求助20
7秒前
李健的应助被blue采纳,获得10
7秒前
康少发布了新的文献求助10
10秒前
是阿玖啊完成签到,获得积分10
10秒前
日桉发布了新的文献求助10
11秒前
11秒前
Maestro_S的应助被renn采纳,获得20
12秒前
orixero的应助被chao采纳,获得10
12秒前
13秒前
李木头完成签到,获得积分10
13秒前
13秒前
桐桐的应助被壮观的凝阳采纳,获得10
14秒前
as完成签到,获得积分20
14秒前
14秒前
137292967完成签到,获得积分10
14秒前
丘比特的应助被zz采纳,获得10
15秒前
15秒前
15秒前
感性的怡完成签到,获得积分10
17秒前
18秒前
逆旅发布了新的文献求助10
18秒前
19秒前
19秒前
iceicefdtd发布了新的文献求助10
19秒前
无极微光的应助被www采纳,获得20
19秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Improving the wear resistance of vehicle gear oil by oil soluble LaF3 nanoparticles and typical additives of gear oil 500
Boundaries and Bodhisattvas 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8184061
求助须知:如何正确求助?哪些是违规求助? 9573151
关于积分的说明 21829878
捐赠科研通 7781058
什么是DOI,文献DOI怎么找? 3434216
关于科研通互助平台的介绍 2558337
邀请新用户注册赠送积分活动 2480674